DENTSPLY SIRONA (NASDAQ:XRAY) Director Buys $62,400.00 in Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director James Forbes acquired 5,000 shares of the business’s stock in a transaction on Monday, March 9th. The shares were purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $124,800. The trade was a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $12.73 on Thursday. DENTSPLY SIRONA Inc. has a one year low of $9.85 and a one year high of $17.18. The company has a market cap of $2.54 billion, a P/E ratio of -4.24, a P/E/G ratio of 1.48 and a beta of 0.97. The firm has a 50-day moving average of $12.71 and a 200-day moving average of $12.43. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The firm had revenue of $961.00 million during the quarter, compared to the consensus estimate of $926.40 million. During the same period in the previous year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

Analysts Set New Price Targets

XRAY has been the subject of a number of research reports. Wells Fargo & Company increased their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Barrington Research upped their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Mizuho increased their price objective on DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Barclays initiated coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 target price for the company. Finally, Robert W. Baird upped their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.42.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently made changes to their positions in XRAY. Parkside Financial Bank & Trust increased its position in shares of DENTSPLY SIRONA by 620.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 1,477 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter worth approximately $26,000. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA in the fourth quarter valued at $26,000. True Wealth Design LLC increased its position in shares of DENTSPLY SIRONA by 273.0% during the second quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 1,739 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of DENTSPLY SIRONA by 337.9% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.